Epidemic related update
The national health and Health Committee released the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth). On the basis of nucleic acid detection, added antigen detection as a supplement, added Pfizer COVID-19 oral medicine Paxlovid and Tengsheng Bo medicine neutralizing antibody into the diagnosis and treatment plan, and revised the content of Chinese medicine treatment.
Shanghai Junshi Biosciences Co.Ltd(688180) vv116 global multicenter phase 3 clinical trial for the treatment of moderate and severe covid-19 patients has completed the first subject administration, and the global multicenter phase 2 / 3 clinical trial for the treatment of mild and moderate covid-19 patients has also completed the first administration in China. The phase 1 clinical data of the drug in China are good and published in the journal Nature.
The research progress of Lianhua Qingwen in the control of Omicron was released, which is effective for Omicron.
Pfizer covid-19 oral drug MPP authorization was announced, and five Chinese enterprises were authorized, including Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) , Apeloa Pharmaceutical Co.Ltd(000739) , Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) , Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Shanghai Desano.
The number of new cases in Hong Kong began to decline. The number of new cases in Europe has been repeated this week. The mortality rate of confirmed patients in the world is stable within 1%. Omicron subspecies ba 2. The proportion in the world continues to rise to nearly 40%.
Zhou viewpoint update
This week, a number of innovative drugs were approved for initial listing or new indications. Pratinib, RET inhibitor of cornerstone pharmaceutical, doncib, PI3K inhibitor of stone Pharmaceutical Group, Lilly VEGFR-2 monoclonal antibody and ramoxizumab were approved for initial listing Betta Pharmaceuticals Co.Ltd(300558) alk inhibitor ensatinib was approved as the first-line indication of NSCLC, and artelizumab Roche was approved as the auxiliary indication of NSCLC.
Innovation is the long-term driving force of the pharmaceutical industry. We are optimistic about pharmaceutical innovation and innovation Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) chain, as well as the high performance in the first quarter of the annual report of CXO sector, and the growth and fulfillment market. In late March, the performance disclosure period was intensively entered. The performance of CXO sector grew rapidly in 2021, and the business momentum has been improving since 2022. Many companies disclosed the orders from January to February. It is expected that the sentiment of the sector will continue to pick up with the disclosure of the annual report and the first quarter.
Continue to be optimistic about the upstream API sector of the industrial chain and the upstream pharmaceutical supply chain: ① the dual path growth of industrial upgrading + industrial extension of the API sector is expected to continue to improve the profitability of the API sector in 2022. ② Focus on the investment opportunities in the supply chain during the 14th Five Year Plan period (industrial upgrading + domestic substitution), including subdivided fields such as equipment and equipment, scientific instruments, upstream reagent consumables for scientific research, upstream consumables for pharmaceutical industry and raw and auxiliary material packaging materials.
Investment advice
It is suggested to focus on the two main lines of high performance growth and epidemic prevention and control. Epidemic prevention and control mainly includes detection and killing, including detection and killing, vaccines and specific drugs and their R & D industrial chain, upstream supply chain, etc., with emphasis on vaccines and specific drugs (domestic and foreign) and their R & D industrial chain.
, ɛɛɛɛɛɛɛɛɛɛɛɛ.
Risk tips
Covid-19 epidemic development and change risk, product R & D data and progress are less than expected risk, product capacity and sales are less than expected risk, orders are less than expected risk, competition is intensified risk, and policy supervision risk. Exchange rate fluctuation risk, etc.
